Tofacitinib: a promising agent for the treatment of persistent rashes in juvenile dermatomyositis.
作者信息
Chen Zhao-Yu, Zhang Tian-Nan, Li Ji, Zhang Zhen-Jie, Song Hong-Mei
机构信息
Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng, Beijing, 100730, China.
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
World J Pediatr. 2025 Apr;21(4):419-422. doi: 10.1007/s12519-025-00901-x. Epub 2025 Apr 14.
Abstract
摘要
相似文献
1
Tofacitinib: a promising agent for the treatment of persistent rashes in juvenile dermatomyositis.托法替布：一种治疗青少年皮肌炎持续性皮疹的有前景的药物。
World J Pediatr. 2025 Apr;21(4):419-422. doi: 10.1007/s12519-025-00901-x. Epub 2025 Apr 14.
2
Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.成人及青少年皮肌炎中 Janus 激酶抑制剂的现有证据及关键比较。
Expert Opin Pharmacother. 2024 Aug;25(12):1625-1645. doi: 10.1080/14656566.2024.2392021. Epub 2024 Aug 18.
3
[Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib].[托法替布治疗难治性幼年皮肌炎的临床特征及疗效分析]
Zhonghua Er Ke Za Zhi. 2023 Jun 2;61(6):538-542. doi: 10.3760/cma.j.cn112140-20221128-01009.
4
Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature.托法替尼治疗抗黑色素瘤分化相关基因 5 抗体阳性的青少年皮肌炎的成功治疗：病例报告及文献复习。
Immunol Med. 2024 Jun;47(2):110-117. doi: 10.1080/25785826.2024.2336687. Epub 2024 Apr 1.
5
Tofacitinib monotherapy as maintenance treatment in juvenile dermatomyositis: a case report.托法替布单药治疗作为青少年皮肌炎的维持治疗：一例报告
RMD Open. 2025 May 21;11(2):e005651. doi: 10.1136/rmdopen-2025-005651.
6
Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.关于在幼年皮肌炎中 Janus 激酶抑制剂的疗效和安全性的最新进展。
Expert Rev Clin Immunol. 2024 Jun;20(6):589-602. doi: 10.1080/1744666X.2024.2312819. Epub 2024 Feb 8.
7
Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis.托法替布治疗抗黑色素瘤分化相关 5 基因抗体阳性成人皮肌炎新发病例。
Clin Rheumatol. 2023 Jul;42(7):1847-1853. doi: 10.1007/s10067-023-06567-y. Epub 2023 Mar 16.
8
Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.托法替布治疗 MDA5 阳性皮肌炎合并坏疽性胆囊炎
Eur J Med Res. 2022 May 15;27(1):68. doi: 10.1186/s40001-022-00693-0.
9
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.Janus 激酶抑制剂托法替尼治疗难治性儿童皮肌炎：中国多中心回顾性研究。
Arthritis Res Ther. 2023 Oct 18;25(1):204. doi: 10.1186/s13075-023-03170-z.
10
The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis.托法替布治疗抗黑色素瘤分化相关基因 5 抗体阳性皮肌炎相关间质性肺病的疗效和安全性：系统评价和荟萃分析。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241294000. doi: 10.1177/17534666241294000.
本文引用的文献
1
Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.在幼年皮肌炎中使用 Janus 激酶抑制剂治疗：文献综述。
Semin Arthritis Rheum. 2024 Jun;66:152426. doi: 10.1016/j.semarthrit.2024.152426. Epub 2024 Mar 1.
2
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.Janus 激酶抑制剂托法替尼治疗难治性儿童皮肌炎：中国多中心回顾性研究。
Arthritis Res Ther. 2023 Oct 18;25(1):204. doi: 10.1186/s13075-023-03170-z.
3
Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis.Janus 激酶抑制剂和新型活动性疾病生物标志物在幼年皮肌炎中的长期随访。
Rheumatology (Oxford). 2023 Mar 1;62(3):1227-1237. doi: 10.1093/rheumatology/keac399.
4
Juvenile dermatomyositis. Where are we now?幼年特发性关节炎。我们现在在哪里？
Clin Exp Rheumatol. 2022 Feb;40(2):394-403. doi: 10.55563/clinexprheumatol/56ilob. Epub 2022 Feb 7.
5
Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis.静脉注射和皮下免疫球蛋白治疗特发性炎性肌病的疗效和安全性：系统评价和荟萃分析。
Autoimmun Rev. 2022 Feb;21(2):102997. doi: 10.1016/j.autrev.2021.102997. Epub 2021 Nov 17.
6
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.幼年特发性皮肌炎中干扰素的最新研究进展：发病机制与治疗。
Curr Opin Rheumatol. 2021 Sep 1;33(5):371-377. doi: 10.1097/BOR.0000000000000816.
7
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.Janus激酶抑制剂显著改善了青少年皮肌炎的皮疹和肌肉力量。
Ann Rheum Dis. 2021 Apr;80(4):543-545. doi: 10.1136/annrheumdis-2020-218582. Epub 2020 Oct 28.
8
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.成功使用 Janus 激酶抑制剂托法替尼治疗难治性青少年皮肌炎：一项初步研究及文献复习。
Rheumatology (Oxford). 2021 Apr 6;60(4):1700-1707. doi: 10.1093/rheumatology/keaa558.
9
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.回顾性分析大样本幼年皮肌炎患者接受英夫利昔单抗和阿达木单抗治疗的情况。
Arthritis Res Ther. 2020 Apr 15;22(1):79. doi: 10.1186/s13075-020-02164-5.
10
JAK Inhibitors: Prospects in Connective Tissue Diseases.JAK 抑制剂：在结缔组织疾病中的前景。
Clin Rev Allergy Immunol. 2020 Dec;59(3):334-351. doi: 10.1007/s12016-020-08786-6.
Zotero 插件